Precision at the Point of Injury
Arogya Biotechnologies engineers next-generation biomaterials for critical unmet needs in surgery and wound care. Our first platform, HemoSeal, addresses life-threatening surgical bleeding where current sealants fall short.
Uncontrolled hemorrhage remains a leading cause of preventable death across surgery, trauma, and combat medicine — not because solutions don't exist, but because every available product breaks down precisely when and where it matters most: in wet, dynamic, infected, or hard-to-reach tissue environments where reliable sealing, flexible adhesion, and infection control are simultaneously required.
HemoSeal is a next-generation injectable hemostatic sealant that addresses the limitations of every currently available product — in a single material.
Fully synthetic formulation eliminates the risks of pathogen transmission, supply constraints, and immunogenic reactions associated with fibrin or thrombin-based products.
Unlike gauze-based or pressure-dependent hemostats, HemoSeal achieves hemostasis through material adhesion alone — no manual compression needed, even in hard-to-reach anatomy.
Tunable mechanical properties allow HemoSeal to conform to and seal a wide range of soft tissues — including lung, liver, bowel, and vascular surfaces — without detachment under cyclic motion.
HemoSeal is the only sealant in development to combine active hemorrhage control with intrinsic broad-spectrum antibacterial protection — addressing two of surgery's most critical complications simultaneously.
Syringeable formulation compatible with standard laparoscopic and endoscopic port sizes, enabling use in the fastest-growing segment of surgery where no effective injectable sealant currently exists.
Photo-activated crosslinking enables near-instantaneous gelation at the point of application — giving surgeons precise spatial and temporal control in time-critical bleeding scenarios.
Laparoscopic and open abdominal procedures involving the liver, spleen, bowel, and kidney — where bleeding control and infection prevention are both critical.
Bronchoscopic and open thoracic procedures requiring a sealant that conforms to lung parenchyma, tolerates respiratory motion, and maintains adhesion in a fluid-rich environment.
Penetrating and blunt trauma with internal hemorrhage, where speed of application, wet-field performance, and no compression requirement are decisive factors.
Forward-deployed and combat environments where injectable, storage-stable hemostats with built-in infection control could reduce preventable casualty mortality without access to an operating room.
Pre-hospital bleeding control by paramedics and first responders, where ease of use and rapid gelation are essential in the critical window before hospital arrival.
In vitro hemostasis, wet-tissue adhesion, antibacterial efficacy, and biocompatibility have been validated and published in Advanced Science (2025).
PhD in Chemical Engineering, UCLA. Inventor of the HemoSeal platform technology. 14 peer-reviewed publications including first-author papers in Science Translational Medicine and Advanced Science. Two filed patents. Deep expertise in hydrogel design, nanoparticle drug delivery, and tissue engineering.
Awarded NSF I-Corps Teams grant and selected for the National Program cohort — a competitive customer discovery initiative designed to accelerate deep-tech commercialization.
Arogya Biotechnologies, Inc. formally incorporated in California.
HemoSeal won First Place in the pitch competition at LA Best MedTech, selected from a competitive field of emerging medical device and biotechnology companies across the Los Angeles region.
Selected to present HemoSeal at Taiwan Selects LA, a curated program connecting high-potential life sciences startups with international strategic partners and investors.
Selected to pitch at MedTech Innovator, one of the most competitive medtech accelerator programs globally, with a 10% acceptance rate among applicants worldwide.
HemoSeal platform technology published in Advanced Science (Wiley), a high-impact peer-reviewed journal.
We are actively building relationships with strategic investors, clinical collaborators, and medtech partners who share our vision for better surgical outcomes.